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ABSTRACT (word count 260) 
Objectives 
The size of the population of men who have sex with men (MSM) who may be eligible for HIV 
pre-exposure prophylaxis (HIV-PrEP) in England remains unknown.  To plan for a national 
PrEP implementation trial, we estimated the number of MSM attending sexual health clinics 
(SHCs) that may be eligible for HIV-PrEP in England. 
Methods 
STI surveillance data from 2010-2015 from the GUMCAD surveillance system were used to 
estimate the annual number of HIV-negative MSM who may be eligible for HIV-PrEP in 
England.  Based on national eligibility criteria, we identified HIV-negative MSM attending 
SHCs with a HIV-negative test in the past year, and used diagnosed bacterial STI (past year) 
in this group as a proxy for condomless sex and eligibility for HIV-PrEP.  We estimated HIV 
incidence per 100 person-years (py) in these groups in 2014. 
Results 
During 2010-2015, the number of HIV-negative MSM attending SHCs with a HIV-negative test 
in the past year doubled from 14,643 to 29,023, and HIV incidence in this group was 1.9 (95% 
CI 1.6-2.2) per 100py in 2014. In the same period, the subgroup with a bacterial STI diagnosis 
(past year), and therefore considered potentially eligible for HIV-PrEP in this analysis, 
increased from 4,365 (30%) to 10,276 (35%). HIV incidence in this subgroup was 3.3 (95% CI 
2.7-4.0) per 100py in 2014.  
Conclusions 
In 2015, approximately 10,000 HIV-negative MSM were considered potentially eligible for HIV-
PrEP based on clinic history in GUMCAD. These data were used to inform the initial 
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recruitment target for the PrEP Impact Trial and will inform future evaluations at a population 
level. 
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KEY MESSAGES 
 Estimating the size of the population that may be eligible for HIV-PrEP is essential to 
support service planning and delivery of a large-scale national programme. 
 For 2015, we estimated that 10,000 HIV-negative MSM were potentially eligible for HIV-
PrEP, in whom HIV incidence was 3.3 per 100 person-years. 
 These data informed the initial recruitment target for the PrEP Impact Trial. Early 
recruitment data suggest that we have underestimated HIV-PrEP need among MSM. 
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INTRODUCTION 
Pre-exposure prophylaxis (PrEP) for HIV is the use of antiretroviral drugs before HIV exposure 
to prevent infection.  Evidence from randomised controlled trials suggests that HIV-PrEP 
reduces the risk of HIV infection by 86% among gay, bisexual and other men who have sex 
with men (MSM) at high risk of HIV and is thought to have the potential as a national 
intervention, in combination with wider prevention methods, to reduce HIV incidence at a 
population level. [1-3] 
MSM are the population group most at risk of acquiring HIV infection in the UK.  In 2017, 53% 
(2,330) of new HIV diagnoses were reported among MSM who are a key target group for HIV 
prevention initiatives.[4] The absolute number of individuals accessing HIV-PrEP in England 
is likely to be determined primarily by the number of MSM at high risk of HIV acquisition. Thus, 
while other populations are eligible for HIV-PrEP, this paper focuses on MSM. 
In 2016, NHS England (NHSE) committed to funding a large three-year trial of HIV-PrEP to 
be delivered through sexual health clinics (SHCs).[5] The PrEP Impact Trial, which started 
recruiting in October 2017, aims to address key outstanding public health and implementation 
questions before a national HIV-PrEP programme can be rolled-out in England.[6]  
The NHSE proposed pathway for the delivery of HIV-PrEP is through SHCs. Practical 
estimates of the potential numbers eligible for HIV-PrEP are therefore needed to project the 
likely costs associated with HIV-PrEP provision and for services to plan for appropriate 
capacity and delivery.  We used national sexually transmitted infection (STI) surveillance data 
to estimate the size of the MSM population likely to be eligible for HIV-PrEP in England. 
 
 
METHODS 
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Data source 
We used data from GUMCAD, the national STI surveillance system in England; this records 
all attendances at genitourinary medicine (GUM) clinics and integrated GUM/sexual and 
reproductive health services (referred to as SHCs).[7]  Each attendance is reported with 
clinical and demographic information. Patient records can be linked within, but not across 
clinics using clinic numbers that are unique to each individual. 
Study population and time period 
Individuals were included if they attended a SHC at least once during 2010-2015, and clinical 
and demographic data associated with their first attendance in each year were retained.  All 
MSM who were HIV-negative or not known to be HIV-positive at their first attendance in a 
given year (defined as no clinical record indicating a HIV diagnosis at the same clinic and 
hereafter referred to as HIV-negative MSM) who were ≥15 years were included.  Men were 
defined as MSM if they self-identified as either gay or bisexual at least once during their clinic 
attendance history.   
Estimating the need for HIV-PrEP in MSM 
Our analysis was based on the NHSE proposed eligibility criteria for HIV-PrEP,[8] which 
consider MSM to be at high risk of HIV acquisition and eligible for HIV-PrEP if they meet the 
following criteria: 
- Currently HIV-negative with a documented negative test during a previous episode of 
care in the last year (42-365 days) 
- Reporting condomless sex in the past 3 months 
- Confirms likelihood to engage in condomless sex in the next 3 months. 
We estimated the number of HIV-negative MSM who had a HIV-negative test in the 42-365 
days prior to their first attendance of the year (hereafter referred to as recent HIV-negative 
test); at the time of conducting this analysis, a recent HIV-negative test was used as a marker 
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of increased risk of HIV acquisition. The 42-day interval reflects the duration of a standard 
episode of care used to analyse all GUMCAD data.[7]  Sexual behaviours are not currently 
collected in GUMCAD, so we used diagnosis of a bacterial STI at first attendance and/or in 
the past year as a proxy for condomless sex to define the group of MSM at higher risk of HIV 
and therefore likely to be eligible for HIV-PrEP. 
Estimating HIV incidence 
Kaplan-Meier analysis was used to estimate HIV incidence among HIV-negative MSM 
attending SHCs in 2014.  The analysis included individuals with an initial HIV-negative test 
during 2014 and who had at least one subsequent HIV test undertaken between 42-365 days 
after their initial test.  Any HIV test within 42 days of the initial test was considered to belong 
to the same testing episode and was discounted.  Individuals were followed from the date of 
their initial HIV test until their HIV diagnosis or last attendance within 1 year of the initial test.[9] 
(Supplementary figure) HIV incidence was similarly estimated for the group of HIV-negative 
MSM with a recent HIV-negative test and for the sub-group with a bacterial STI diagnosis in 
the past year. 
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RESULTS 
The number of HIV-negative MSM attending SHCs increased by 68% from 69,392 in 2010 to 
116,546 in 2015, and the number of those MSM who had also had a recent HIV-negative test 
nearly doubled from 14,643 to 29,023 in the same period (Table 1).  The number of HIV-
negative MSM with a recent HIV-negative test and a bacterial STI diagnosis in the past year 
(i.e. those considered eligible for HIV-PrEP) increased from 4,365 (30%) in 2010 to 10,276 
(35%) in 2015. 
To estimate HIV incidence in 2014, we identified 37,228 HIV-negative MSM with a subsequent 
HIV test within one year who contributed 24,709 person-years of follow-up time.  There were 
429 new HIV diagnoses, giving an overall HIV incidence of 1.8 (95% CI 1.6-2.0) per 100py.  
HIV incidence was 1.9 (95% CI 1.6-2.2) per 100py among the group of HIV-negative MSM 
with a recent HIV-negative test, and 3.3 (95% CI 2.7-4.0) per 100py among the subgroup of 
MSM with a bacterial STI diagnosis in the past year. 
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Table  1.    Number of HIV-negative MSM clinic attendees at sexual health clinics in England by clinical risk group, 2010-2015 
Clinical risk group 2010 2011 2012 2013 2014 2015 
MSM clinic attendees HIV-negative or not known to be HIV-
positive* 
69,392 79,092 88,840 95,831 109,919 116,546 
MSM clinic attendees HIV-negative or not known to be HIV-
positive* AND with a recent HIV-negative test 42-365 days prior to 
initial attendance in calendar year (and the proportion of all HIV-
negative MSM clinic attendees) 
14,634 
21% of all 
HIV 
negative 
attendees 
15,439 
20% of all 
HIV 
negative 
attendees 
18,957 
21% of all 
HIV 
negative 
attendees 
21,670 
23% of all 
HIV 
negative 
attendees 
25,092 
23% of all 
HIV 
negative 
attendees 
29,023 
25% of all 
HIV 
negative 
attendees 
- Number (and proportion) of whom had a bacterial‡  
diagnosis in previous year and/or at first attendance of 
year 
4,365 
30%  
4,840 
31%  
6,131 
32% 
6,979 
32%  
8,202 
33%  
10,276 
35%  
*The number of MSM who in GUMCAD by the end of their first attendance of the calendar year have no clinical records to indicate a HIV diagnosis at the 
same clinic. 
‡ Bacterial STI diagnosis was defined as a diagnosis of chlamydia, gonorrhoea, syphilis (primary, secondary or early latent), lymphogranuloma venereum 
(LGV), non-specific genital infection (NSGI), donovanosis or chancroid at any anatomical site.
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DISCUSSION 
Based on prior clinical history in GUMCAD, we observed an annual increase in HIV-negative 
MSM attending SHCs, and estimated that around 10,000 MSM were potentially eligible for 
HIV-PrEP in England in 2015. HIV incidence among the group of MSM who may be eligible 
for HIV-PrEP was nearly double that of all HIV-negative MSM.   
This is the first analysis to estimate the size of the population of HIV-negative MSM eligible for 
HIV-PrEP in England and is based on a pragmatic approach using the most comprehensive 
source of data available.  However, our analysis used proxy measures of risk based on 
available clinical history in GUMCAD. We were not able to follow individuals across clinics, 
and therefore might have underestimated the number of MSM who had a recent HIV-negative 
test or bacterial STI diagnosis at a different clinic.  In addition, GUMCAD does not collect data 
on sexual behaviour, and we used recent diagnosis of a bacterial STI as a proxy for 
condomless sex. Although recent bacterial STI was also used in devising the NHSE HIV-PrEP 
eligibility criteria,[8] we recognise that it is an imperfect measure of recent risk because it 
excludes individuals who may be at high risk of HIV but were not diagnosed with a bacterial 
STI.  We do not mean to imply that an STI diagnosis is required to be eligible for HIV-PrEP; 
the analysis represents our best estimate of HIV-PrEP need among MSM in England using 
available national surveillance data. 
Our analysis included STI diagnoses from any anatomical infection site (genital, rectal and 
pharyngeal), which might have overestimated the number of MSM who were eligible for HIV-
PrEP because some MSM with pharyngeal infections might use condoms for anal sex.  
However, in 2015, pharyngeal-only infections represented 7.6% (784/10,276) of all bacterial 
STI diagnoses among HIV-negative MSM with a recent HIV-negative test, and so the effect is 
likely to be small.  We also recognise that other individuals are likely to be eligible for HIV-
PrEP, including those who have not yet attended a SHC, or partners of people living with HIV 
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who are not yet on treatment nor have detectable viral loads.  Nevertheless, our approach 
provides a replicable method that can be used to compare a defined high risk group over time. 
Alternative estimates of the proportion of MSM attending SHCs and eligible for PrEP were 
recently generated using data from the AURAH study; a cross-sectional study at 20 SHCs that 
recruited HIV-negative (or undiagnosed) individuals attending for routine tests (2013-
2014).[10] The study found that 45.1% (670/1484) of MSM in the study population had a 
confirmed HIV-negative test result and reported condomless sex in the past 3 months, and 
thus may represent the proportion of SHC attendees eligible for PrEP.[11] While the data 
source and methodology used to generate these estimates differs from our own, they suggest 
that PrEP eligibility in MSM is higher than we have estimated. 
Our estimates were used to inform the recruitment target for the PrEP Impact Trial 
(10,000).[12] As of October 2018, 9,000 individuals are currently enrolled in the trial with the 
need being greatest among MSM.[4] These data suggest that our proxy measures of high risk 
may have underestimated HIV-PrEP eligibility among MSM. Although our estimates provided 
insight into the size of the MSM population likely to be eligible for HIV-PrEP in England in 
2015, the actual need for and uptake of HIV-PrEP depends on interactions between clinical, 
social, and behavioural factors during low and high risk periods for individuals.[13] 
Furthermore, the delivery of PrEP through SHCs may have increased the number of first-time 
attendees who may be at higher risk of HIV and other STIs; in the first year of the Scottish 
NHS programme, nearly 20% of individuals prescribed PrEP had never attended a SHC, or 
had not attended in the past 10 years.[14] An additional 3,000 places have now been made 
available on the PrEP Impact Trial.[15] Looking ahead, sexual behaviours and HIV-PrEP 
consultations will be monitored longitudinally through a future enhancement to GUMCAD.[16] 
We have used national surveillance data, which records all attendances at SHCs, to estimate 
the number of MSM who may be eligible for HIV-PrEP. This approach takes advantage of high 
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quality surveillance data that will inform national and local level service planning and will be a 
valuable component of future evaluations of any HIV-PrEP programme. 
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